(MENAFN- MENAFNAuthors)
COPENHAGEN, Denmark, January 24, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) reports further progress in the development of a prophylactic vaccine against the equine encephalitis virus - a rare, but potentially deadly illness. The program, which is funded by the United States Department of Defense (DoD) Joint Project Management Office for Medical Countermeasure Systems (JPM-MCS) through a multi-year agreement of up to USD 36 million, aims to develop a vaccine against three separate strains of the equine encephalitis virus, Eastern (EEEV), Venezuelan (VEEV), and Western (WEEV), for which there are currently no preventative vaccines available. The vaccine is based on Bavarian Nordic's proprietary, poxviral MVA-BN® platform, which due to its large genome is able to encode multiple antigens, thus providing the potential to protect against multiple diseases.
MENAFN2401201902030000ID1098018194
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.